Press Releases

December 16, 2020
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113) Read More
December 15, 2020
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Read More
December 10, 2020
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock Read More
December 10, 2020
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Read More
December 7, 2020
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories Read More
December 6, 2020
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera Read More
December 2, 2020
Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera Read More
December 1, 2020
Protagonist Therapeutics Reports Granting of Inducement Award Read More
November 30, 2020
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020 Read More
November 25, 2020
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference Read More
November 11, 2020
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference Read More
November 4, 2020
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update Read More
November 4, 2020
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting Read More
October 30, 2020
Protagonist Therapeutics Reports Granting of Inducement Award Read More
October 29, 2020
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen Read More
October 21, 2020
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera Read More
September 17, 2020
Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020 Read More
September 15, 2020
Protagonist Therapeutics Reports Granting of Inducement Award Read More
September 10, 2020
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference Read More
September 2, 2020
Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar Read More